KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

"Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcinoma (PDAC) patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX)."

Intervention / Treatment

• Drug: KRAS Vaccine with Poly-ICLC adjuvant

• Drug: Balstilimab

• Drug: Botensilimab

Phase 2 trial at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

to open September 2024

50 patients

NOTE: All interventional clinical trials involve risk. So please discuss the trial with your oncology team as well as ask questions of the trial researchers.

https://clinicaltrials.gov/study/NCT06411691?term=NCT06411691&rank=1